Presentation of hypoparathyroidism: Etiologies and clinical features

Journal of Clinical Endocrinology and Metabolism

Volumn 101, Issue 6, 2016, Pages 2300-2312

  Shoback, Dolores M ^a   Bilezikian, John P ^b   Costa, Aline G ^b   Dempster, David ^b,c,d   Dralle, Henning ^e   Khan, Aliya A ^f   Peacock, Munro ^g   Raffaelli, Marco ^h   Silva, Barbara C ⁱ   Thakker, Rajesh V ^j   Vokes, Tamara ^k   Bouillon, Roger ^l  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Columbia University ^*  (United States)

^c FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^d HELEN HAYES HOSPITAL   (United States)

^e MARTIN LUTHER UNIVERSITÄT HALLE WITTENBERG   (Germany)

^f MCMASTER UNIVERSITY   (Canada)

^g INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

ⁱ Santa Casa de Belo Horizonte   (Brazil)

^j UNIVERSITY OF OXFORD   (United Kingdom)

^k UNIVERSITY OF CHICAGO   (United States)

^l UNIVERSITY OF LEUVEN   (Belgium)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BONE BIOPSY; BONE MASS; BONE MICROARCHITECTURE; BONE TURNOVER; CAUSAL ATTRIBUTION; CLINICAL FEATURE; CONFERENCE PAPER; GENE MUTATION; HUMAN; HYPERPHOSPHATEMIA; HYPOCALCEMIA; HYPOPARATHYROIDISM; KIDNEY CALCIFICATION; KIDNEY FAILURE; MAGNESIUM DEFICIENCY; MICRO-COMPUTED TOMOGRAPHY; MORPHOMETRICS; NEPHROLITHIASIS; PATHOGENESIS; PRIORITY JOURNAL; PSEUDOHYPOPARATHYROIDISM; QUALITY OF LIFE; SEIZURE; SYMPTOMATOLOGY; THYROIDECTOMY; AUTOIMMUNE DISEASE; COMPLICATION; PARATHYROID GLAND; SURGERY; SYMPTOM ASSESSMENT;

AUTOIMMUNE DISEASES; HUMANS; HYPOPARATHYROIDISM; PARATHYROID GLANDS; QUALITY OF LIFE; SYMPTOM ASSESSMENT;

EID: 84973545746     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2015-3909     Document Type: Article

References (103)

1. Cooper MS. Disorders of calcium metabolism and parathyroid disease. Best Pract Res Clin Endocrinol Metab. 2011;25:975-983.
2. Kovacs CS. Bone development and mineral homeostasis in the fetus and neonate: Roles of the calciotropic and phosphotropic hormones. Physiol Rev. 2014;94:1143-1218.
3. Shaw N. A practical approach to hypocalcaemia in children. Endocr Dev. 2009;16:73-92.
4. Lienhardt-Roussie A, Linglart A. Hypoparathyroidism in children. In: Licata AA, Lerma EV, eds. Diseases of the parathyroid glands. New York, NY: Springer Science; 2012:299-310.
5. Shoback D. Clinical practice. Hypoparathyroidism.N Engl J Med. 2008;359:391-403.
6. Bilezikian JP, Khan A, Potts JT Jr, et al. Hypoparathyroidism in the adult: Epidemiology, diagnosis, pathophysiology, target-organ involvement, treatment, and challenges for future research. J Bone Miner Res. 2011;26:2317-2337.
7. De Sanctis V, Soliman A, Fiscina B. Hypoparathyroidism: From diagnosis to treatment. Curr Opin Endocrinol Diabetes Obes. 2012;19:435-442.
8. Goswami R, Millo T, Mishra S, et al. Expression of osteogenic molecules in the caudate nucleus and gray matter and their potential relevance for basal ganglia calcification in hypoparathyroidism. J Clin Endocrinol Metab. 2014;99:1741-1748.
9. Srirangarajan S, Satyanarayan A, Ravindra S, Thakur S. Dental manifestation of primary idiopathic hypoparathyroidism. J Indian Soc Periodontol. 2014;18:524-526.
10. Mannstadt MM, Mitchell DM. Clinical manifestations of hypoparathyroidism. In: Bilezikian JP, Marcus R, LevineMA, Marcocci C, Silverberg SJ, Potts JT Jr, eds. The parathyroids. London, UK: Academic Press; 2015:761-770.
11. Chen Q, Kaji H, Iu MF, et al. Effects of an excess and a deficiency of endogenous parathyroid hormone on volumetric bone mineral density and bone geometry determined by peripheral quantitative computed tomography in female subjects. J Clin Endocrinol Metab. 2003;88:4655-4658.
12. Rubin MR, Dempster DW, Zhou H, et al. Dynamic and structural properties of the skeleton in hypoparathyroidism. J Bone Miner Res. 2008;23:2018-2024.
13. Sikjaer T, Rejnmark L, Rolighed L, et al. The effect of adding PTH(1-84) to conventional treatment of hypoparathyroidism: A randomized, placebo-controlled study. J Bone Miner Res. 2011; 26:2358-2370.
14. Cusano NE, Rubin MR, McMahon DJ, et al. Therapy of hypoparathyroidism with PTH(1-84): A prospective four-year investigation of efficacy and safety. J Clin Endocrinol Metab. 2013;98: 137-144.
15. Winer KK, Sinaii N, Reynolds J, Peterson D, Dowdy K, Cutler GB Jr. Long-term treatment of 12 children with chronic hypoparathyroidism: A randomized trial comparing synthetic human parathyroid hormone 1-34 versus calcitriol and calcium. J Clin Endocrinol Metab. 2010;95:2680-2688.
16. Silva BC, Cusano NE, Zhang C, et al. Beneficial effects of PTH (1-84) in hypoparathyroidism as determined by microarchitectural texture assessment (TBS): A 4-year experience. J Bone Miner Res. 2013;28(suppl 1):FR0172.
17. Cusano NE, Nishiyama KK, Zhang C, et al. Noninvasive assessment of skeletal microstructure and estimated bone strength in hypoparathyroidism. J Bone Miner Res. 2016;31:308-316.
18. Macdonald HM, Nishiyama KK, Kang J, Hanley DA, Boyd SK. Age-related patterns of trabecular and cortical bone loss differ between sexes and skeletal sites: A population-based HR-pQCT study. J Bone Miner Res. 2011;26:50-62.
19. Rubin MR, Dempster DW, Sliney J Jr, et al. PTH(1-84) administration reverses abnormal bone-remodeling dynamics and structure in hypoparathyroidism. J Bone Miner Res. 2011;26:2727-2736.
20. Gafni RI, Brahim JS, Andreopoulou P, et al. Daily parathyroid hormone 1-34 replacement therapy for hypoparathyroidism induces marked changes in bone turnover and structure. J Bone Miner Res. 2012;27:1811-1820.
21. Winer KK, Yanovski JA, Sarani B, Cutler GB Jr. A randomized, cross-over trial of once-daily versus twice-daily parathyroid hormone 1-34 in treatment of hypoparathyroidism. J Clin Endocrinol Metab. 1998;83:3480-3486.
22. Winer KK, Sinaii N, Peterson D, Sainz B Jr, Cutler GB Jr. Effects of once versus twice-daily parathyroid hormone 1-34 therapy in children with hypoparathyroidism. J Clin Endocrinol Metab. 2008;93:3389-3395.
23. Costa AG, Cremers S, Rubin MR, et al. Circulating sclerostin in disorders of parathyroid gland function. J Clin Endocrinol Metab. 2011;96:3804-3810.
24. Dempster DW. Bone histomorphometry in hypoparathyroidism. In: Brandi ML, Brown EM, eds. Hypoparathyroidism. New York, NY: Springer; 2015:287-296.
25. Langdahl BL, Mortensen L, Vesterby A, Eriksen EF, Charles P. Bone histomorphometry in hypoparathyroid patients treated with vitamin D. Bone. 1996;18:103-108.
26. Rubin MR, Dempster DW, Kohler T, et al. Three dimensional cancellous bone structure in hypoparathyroidism. Bone. 2010;46: 190-195.
27. Underbjerg L, Sikjaer T, Mosekilde L, Rejnmark L. Postsurgical hypoparathyroidism-risk of fractures, psychiatric diseases, cancer, cataract, and infections. J Bone Miner Res. 2014;29:2504-2510.
28. Underbjerg L, Sikjaer T, Mosekilde L, Rejnmark L. The epidemiology of nonsurgical hypoparathyroidism in Denmark: A nationwide case finding study. J Bone Miner Res. 2015;30:1738-1744.
29. Fujiyama K, Kiriyama T, Ito M, et al. Attenuation of postmenopausal high turnover bone loss in patients with hypoparathyroidism. J Clin Endocrinol Metab. 1995;80:2135-2138.
30. Mendonça ML, Pereira FA, Nogueira-Barbosa MH, et al. Increased vertebral morphometric fracture in patients with postsurgical hypoparathyroidism despite normal bone mineral density. BMC Endocr Disord. 2013;13:1.
31. Mitchell DM, Regan S, Cooley MR, et al. Long-term follow-up of patients with hypoparathyroidism. J Clin Endocrinol Metab. 2012; 97:4507-4514.
32. Boyce AM, Shawker TH, Hill SC, et al. Ultrasound is superior to computed tomography for assessment of medullary nephrocalcinosis in hypoparathyroidism. J Clin Endocrinol Metab. 2013;98: 989-994.
33. Arlt W, Fremerey C, Callies F, et al. Well-being, mood and calcium homeostasis in patients with hypoparathyroidism receiving standard treatment with calcium and vitamin D. Eur J Endocrinol. 2002;146:215-222.
34. Cho NL, Moalem J, Chen L, Lubitz CC, Moore FD, Ruan DT. Surgeons and patients disagree on the potential consequences from hypoparathyroidism. Endocr Pract. 2014;20:427-446.
35. Hadker N, Egan J, Sanders J, Lagast H, Clarke BL. Understanding the burden of illness associated with hypoparathyroidism reported among patients in the paradox study. Endocr Pract. 2014;20:671-679.
36. Cusano NE, Rubin MR, McMahon DJ, et al. PTH(1-84) is associated with improved quality of life in hypoparathyroidism through 5 years of therapy. J Clin Endocrinol Metab. 2014;99: 3694-3699.
37. Sikjaer T, Rolighed L, Hess A, Fuglsang-Frederiksen A, Mosekilde L, Rejnmark L. Effects of PTH(1-84) therapy on muscle function and quality of life in hypoparathyroidism: Results from a randomized controlled trial. Osteoporos Int. 2014;25:1717-1726.
38. Thakker RV, Bringhurst FR, Juppner H. Genetic disorders of calcium homeostasis caused by abnormal regulation of parathyroid hormone secretion or responsiveness. In: DeGroot LJ, Jameson JL, eds. Endocrinology. 7th ed. New York, NY: Elsevier. In press.
39. Turan S, Bastepe M. GNAS spectrum of disorders. Curr Osteoporos Rep. 2015;13:146-158.
40. Mantovani G, Elli FM. Classification of pseudohypoparathyroidism and differential diagnosis. In: Brandi ML, Brown EM, eds. Hypoparathyroidism. New York, NY: Springer; 2015:345-354.
41. Weinstein L. Pseudohypoparathyroidism type 1a, pseudopseudohypoparathyroidism, and Albright hereditary osteodystrophy. In: Brandi ML, Brown EM, eds. Hypoparathyroidism. New York, NY: Springer; 2015:355-362.
42. Juppner H. Pseudohypoparathyroidism type 1b (PHP-ib): PTHresistant hypocalcemia and hyperphosphatemia due to abnormal GNAS methylation. In: Brandi ML, Brown EM, eds. Hypoparathyroidism. New York, NY: Springer; 2015:363-372.
43. Garin I, Mantovani G, Aguirre U, et al. European guidance for the molecular diagnosis of pseudohypoparathyroidism not caused by point genetic variants at GNAS: An EQA study. Eur J Hum Genet. 2015;23:438-444.
44. Steen O, Khan AA. Role of magnesium in parathyroid physiology. In: Brandi ML, Brown EM, eds. Hypoparathyroidism. New York, NY: Springer; 2015:61-67.
45. Arjona FJ, de Baaij JH, Schlingmann KP, et al.CNNM2mutations cause impaired brain development and seizures in patients with hypomagnesemia. PLoS Genet. 2014;10:e1004267.
46. Underbjerg L, Sikjaer T, Mosekilde L, Rejnmark L. Cardiovascular and renal complications to postsurgical hypoparathyroidism: A Danish nationwide controlled historic follow-up study. J Bone Miner Res. 2013;28:2277-2285.
47. Levine MA. Molecular and clinical aspects of pseudohypoparathyroidism. In: Bilezikian JP, Marcus R, Levine MA, Marcocci C, Silverberg SJ, Potts JT Jr, eds. The parathyroids. London, UK: Academic Press; 2015:781-805.
48. Thomusch O, Machens A, Sekulla C, Ukkat J, Brauckhoff M, Dralle H. The impact of surgical technique on postoperative hypoparathyroidism in bilateral thyroid surgery: A multivariate analysis of 5846 consecutive patients. Surgery. 2003;133:180-185.
49. BarczynḱI M, Konturek A, StopaM, Cichń S, Richter P, Nowak W. Total thyroidectomy for benign thyroid disease: is it really worthwhile? Ann Surg. 2011;254:724-729; discussion 729-730.
50. Raffaelli M, De Crea C, Carrozza C, et al. Combining early post-operative parathyroid hormone and serum calcium levels allows for an efficacious selective post-thyroidectomy supplementation treatment. World J Surg. 2012;36:1307-1313.
51. Giordano D, Valcavi R, Thompson GB, et al. Complications of central neck dissection in patients with papillary thyroid carcinoma: Results of a study on 1087 patients and review of the literature. Thyroid. 2012;22:911-917.
52. Edafe O, Antakia R, Laskar N, Uttley L, Balasubramanian SP. Systematic review and meta-analysis of predictors of post-thyroidectomy hypocalcaemia. Br J Surg. 2014;101:307-320.
53. Lorente-Poch L, Sancho JJ, Ruiz S, Sitges-Serra A. Importance of in situ preservation of parathyroid glands during total thyroidectomy. Br J Surg. 2015;102:359-367.
54. Selberherr A, Scheuba C, Riss P, Niederle B. Postoperative hypoparathyroidism after thyroidectomy: Efficient and cost-effective diagnosis and treatment. Surgery. 2015;157:349-353.
55. Doran HE, England J, Palazzo F. Questionable safety of thyroid surgery with same day discharge. Ann R Coll Surg Engl. 2012;94: 543-547.
56. Terris DJ, Snyder S, Carneiro-Pla D. American thyroid association statement on outpatient thyroidectomy. Thyroid. 2013;23:1193-1202.
57. Wong KP, Lang BH. Graves' ophthalmopathy as an indication increased the risk of hypoparathyroidism after bilateral thyroidectomy. World J Surg. 2011;35:2212-2218.
58. Testini M, Gurrado A, Avenia N, et al. Does mediastinal extension of the goiter increase morbidity of total thyroidectomy? A multicenter study of 19, 662 patients. Ann Surg Oncol. 2011;18:2251-2259.
59. Dralle H, Stang A, Sekulla C, Rusner C, Lorenz K, Machens A. Surgery for benign goiter in Germany: Fewer operations, changed resectional strategy, fewer complications [in German]. Chirurg. 2014;85:236-245.
60. Roh JL, Park JY, Park CI. Total thyroidectomy plus neck dissection in differentiated papillary thyroid carcinoma patients: pattern of nodal metastasis, morbidity, recurrence, and postoperative levels of serum parathyroid hormone. Ann Surg. 2007;245:604-610.
61. Dralle H, Sekulla C. Thyroid surgery: generalist or specialist? Zentralbl Chir. 2005;130:428-433.
62. González-Sánchez C, Franch-Arcas G, Gómez-Alonso A. Morbidity following thyroid surgery: does surgeon volume matter? Langenbecks Arch Surg. 2013;398:419-422.
63. Pata G, Casella C, Mittempergher F, Cirillo L, Salerni B. Loupe magnification reduces postoperative hypocalcemia after total thyroidectomy. Am Surg. 2010;76:1345-1350.
64. Griffin TP, Murphy MS, Sheahan P. Vitamin D and risk of postoperative hypocalcemia after total thyroidectomy. JAMA Otolaryngol Head Neck Surg. 2014;140:346-351.
65. Olson JA Jr, DeBenedetti MK, Baumann DS, Wells SA Jr. Parathyroid autotransplantation during thyroidectomy. Results of long-term follow-up. Ann Surg. 1996;223:472-478; discussion 478-480.
66. Lo CY, Lam KY. Routine parathyroid autotransplantation during thyroidectomy. Surgery. 2001;129:318-323.
67. Promberger R, Ott J, Kober F, et al. Intra-and postoperative parathyroid hormone-kinetics do not advocate for autotransplantation of discolored parathyroid glands during thyroidectomy. Thyroid. 2010;20:1371-1375.
68. Tartaglia F, Giuliani A, Sgueglia M, Biancari F, Juvonen T, Campana FP. Randomized study on oral administration of calcitriol to prevent symptomatic hypocalcemia after total thyroidectomy. Am J Surg. 2005;190:424-429.
69. Sanabria A, Dominguez LC, Vega V, Osorio C, Duarte D. Routine postoperative administration of vitamin D and calcium after total thyroidectomy: A meta-analysis. Int J Surg. 2011;9:46-51.
70. Genser L, Trésallet C, Godiris-Petit G, et al. Randomized controlled trial of alfacalcidol supplementation for the reduction of hypocalcemia after total thyroidectomy.Am J Surg. 2014;207:39-45.
71. Hannan FM, Thakker RV. Investigating hypocalcaemia. BMJ. 2013;346:2213.
72. Grigorieva IV, Thakker RV. Transcription factors in parathyroid development: lessons from hypoparathyroid disorders. Ann NY Acad Sci. 2011;1237:24-38.
73. Ogata T, Niihori T, Tanaka N, et al. TBX1 mutation identified by exome sequencing in a Japanese family with 22q11.2 deletion syndrome-like craniofacial features and hypocalcemia. Plos one. 2014;9:e91598.
74. Naiki M, Ochi N, Kato YS, et al. Mutations in HADHB, which encodes the α subunit of mitochondrial trifunctional protein, cause infantile onset hypoparathyroidism and peripheral polyneuropathy. Am J Med Genet. 2014;164A:1180-1187.
75. Hannan FM, Nesbit MA, Zhang C, et al. Identification of 70 calcium-sensing receptor mutations in hyper-and hypo-calcaemic patients: Evidence for clustering of extracellular domain mutations at calcium-binding sites. Hum Mol Genet. 2012;21:2768-2778.
76. Nesbit MA, Hannan FM, Howles SA, et al. Mutations affecting G-protein subunit-11 in hypercalcemia and hypocalcemia.NEngl J Med. 2013;368:2476-2486.
77. Mannstadt M, Harris M, Bravenboer B, et al. Germline mutations affecting G-11 in hypoparathyroidism. N Engl J Med. 2013;368: 2532-2534.
78. Li D, Opas EE, Tuluc F, et al. Autosomal dominant hypoparathyroidism caused by germline mutation in GNA11: phenotypic and molecular characterization. J Clin Endocrinol Metab. 2014;99: E1774-E1783.
79. Taylor JC, Martin HC, Lise S, et al. Factors influencing success of clinical genome sequencing across a broad spectrum of disorders. Nat Genet. 2015;47:717-726.
80. Al-Azem H, Khan AA. Hypoparathyroidism. Best Pract Res Clin Endocrinol Metab. 2012;26:517-522.
81. Walder RY, Landau D, Meyer P, et al. Mutation of TRPM6 causes familial hypomagnesemia with secondary hypocalcemia. Nat Genet. 2002;31:171-174.
82. Ferrè S, Hoenderop JJ, Bindels RJ. Role of the distal convoluted tubule in renal Mg2+ handling: molecular lessons from inherited hypomagnesemia. Magnes Res. 2011;24:S101-S108.
83. Hess MW, Hoenderop JG, Bindels RJ, Drenth JP. Systematic review: hypomagnesaemia induced by proton pump inhibition. Aliment Pharmacol Ther. 2012;36:405-413.
84. Hoorn EJ, van der Hoek J, de Man RA, Kuipers EJ, Bolwerk C, Zietse R. A case series of proton pump inhibitor-induced hypomagnesemia. Am J Kidney Dis. 2010;56:112-116.
85. Hoorn EJ, Walsh SB, McCormick JA, et al. The calcineurin inhibitor tacrolimus activates the renal sodium chloride cotransporter to cause hypertension. Nat Med. 2011;17:1304-1309.
86. Vetter T, Lohse M. Magnesium and the parathyroid. Curropin Nephrol Hypertens. 2002;11:403-410.
87. Wemeau JL. Rare causes of acquired hypoparathyroidism. In: Brandi ML, Brown EM, eds. Hypoparathyroidism. New York, NY: Springer; 2015:271-278.
88. Carpenter TO, Carnes DL Jr, Anast CS. Hypoparathyroidism in Wilson's disease. N Engl J Med. 1983;309:873-877.
89. Ghosh L, Shah M, Pate S, Mannari J, Sharma K. Wilson's disease presenting with hypokalemia, hypoparathyroidism and renal failure. J Assoc Physicians India. 2012;60:57-59.
90. Fatima J, Karoli R, Jain V. Hypoparathyroidism in a case of Wilson's disease: Rare association of a rare disorder. Indian J Endocrinol Metab. 2013;17:361-362.
91. Toumba M, Sergis A, Kanaris C, Skordis N. Endocrine complications in patients with thalassaemia major. Pediatr Endocrinol Rev. 2007;5:642-648.
92. Gamberini MR, De Sanctis V, Gilli G. Hypogonadism, diabetes mellitus, hypothyroidism, hypoparathyroidism: incidence and prevalence related to iron overload and chelation therapy in padoi tients with thalassaemia major followed from 1980 to 2007 in the Ferrara Centre. Pediatr Endocrinol Rev. 2008;6(suppl 1):158-169.
93. Baldini M, Forti S, Marcon A, et al. Endocrine and bone disease in appropriately treated adult patients with β thalassemia major.Ann Hematol. 2010;89:1207-1213.
94. Borgna-Pignatti C, Gamberini MR. Complications of thalassemia major and their treatment. Expert Rev Hematol. 2011;4:353-366.
95. Belhoul KM, Bakir ML, Saned MS, Kadhim AM, Musallam KM, Taher AT. Serum ferritin levels and endocrinopathy in medically treated patients with β thalassemia major. Ann Hematol. 2012; 91:1107-1114.
96. Casale M, Citarella S, Filosa A, et al. Endocrine function and bone disease during long-term chelation therapy with deferasirox in patients with-β thalassemia major. Am J Hematol. 2014;89:1102-1106.
97. Chirico V, Rigoli L, Lacquaniti A, et al. Endocrinopathies, metabolic disorders, and iron overload in major and intermedia thalassemia: Serum ferritin as diagnostic and predictive marker associated with liver and cardiac T2∗ MRI assessment. Eur J Haematol. 2015;94:404-412.
98. Sharma R, Seth A, Chandra J, et al. Endocrinopathies in adolescents with thalassaemia major receiving oral iron chelation therapy. Paediatr Int Child Health. 2016;36:22-27.
99. Horwitz CA, Myers WP, Foote FW Jr. Secondary malignant tumors of the parathyroid glands. Report of two cases with associated hypoparathyroidism. Am J Med. 1972;52:797-808.
100. Watanabe T, Adachi I, Kimura S, et al. A case of advanced breast cancer associated with hypocalcemia. Jpn J Clin Oncol. 1983;13: 441-448.
101. Glazebrook GA. Effect of decicurie doses of radioactive iodine 131 on parathyroid function. Am J Surg. 1987;154:368-373.
102. Winslow CP, Meyers AD. Hypocalcemia as a complication of radioiodine therapy. Am J Otolaryngol. 1998;19:401-403.
103. Aggarwal S, Kailash S, Sagar R, et al. Neuropsychological dysfunction in idiopathic hypoparathyroidism and its relationship with intracranial calcification and serum total calcium. Eur J Endocrinol. 2013;168:895-903.